Rankiteo Logo
Rankiteo
Leader in Cyber Underwriting
Loading...
NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop
WindowsmacOSLinux
Download

Comparison Overview

GrifolsGrifols
VS
Hikma PharmaceuticalsHikma Pharmaceuticals
Grifols

Grifols

Parc Empresarial Can Sant Joan, Sant Cugat del Vallès, 08174, ES

Last Update: 04/04/2026

View Profile
Between 750 and 799
https://linktr.ee/Grifols
775/1000Fair

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healt...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:13,839
Subsidiaries:4
12-month incidents
0
Known data breaches
0
Attack type number
0
Hikma Pharmaceuticals

Hikma Pharmaceuticals

1 New Burlington Place, London, W1S 2HR, GB

Last Update: 03/04/2026

View Profile
Between 750 and 799
http://www.hikma.com
767/1000Fair

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospita...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:10,252
Subsidiaries:0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Ranges Comparison

Based On Specific Ai Models Category
Grifols

Grifols

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA
Hikma Pharmaceuticals

Hikma Pharmaceuticals

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Grifols in 2026.

Incidents

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incidents

Incident History - Grifols (X = Date, Y = Severity)

Grifols cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Incident History - Hikma Pharmaceuticals (X = Date, Y = Severity)

Hikma Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Notable Incidents

Last Cyber / HR Incidents / Global...
Grifols

Grifols

Incidents
No explicit notable incidents reported.
Hikma Pharmaceuticals

Hikma Pharmaceuticals

Incidents
No explicit notable incidents reported.

FAQ

Between Grifols company and Hikma Pharmaceuticals company, which one has the best AI Cybersecurity Score ?
Between Grifols company and Hikma Pharmaceuticals company, which one has experienced more cyber incidents in the past ?
Between Grifols company and Hikma Pharmaceuticals company, which one has experienced more cyber incidents this year ?
Between Grifols company and Hikma Pharmaceuticals company, which one has experienced at least one ransomware attack ?
Between Grifols company and Hikma Pharmaceuticals company, which one has experienced at least one data breach ?
Between Grifols company and Hikma Pharmaceuticals company, which one has experienced at least one targeted cyberattack ?
Between Grifols company and Hikma Pharmaceuticals company, which one has experienced at least one vulnerability ?
Between Grifols company and Hikma Pharmaceuticals company, which one holds the most compliance certifications ?
Between Grifols company and Hikma Pharmaceuticals company, which one holds the fewest compliance certifications ?
Between Grifols company and Hikma Pharmaceuticals company, which one has the most subsidiaries ?
Between Grifols company and Hikma Pharmaceuticals company, which one has the largest number of employees ?
Between Grifols and Hikma Pharmaceuticals, which company holds both SOC 2 Type 1 certifications ?
Between Grifols and Hikma Pharmaceuticals, which company holds both SOC 2 Type 2 certifications ?
Which company is ISO 27001 certified - Grifols or Hikma Pharmaceuticals ?
Which company is PCI DSS compliant - Grifols or Hikma Pharmaceuticals ?
Between Grifols and Hikma Pharmaceuticals, which company complies with HIPAA regulations for healthcare data ?
Between Grifols and Hikma Pharmaceuticals, which company complies with GDPR requirements ?

Latest Global CVEs

CVE-2026-63261
SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). A low-privileged authenticated user can send a specially crafted request to a Kibana machine learning feature, causing the server to exhaust available memory and become unavailable to all users.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 6.5)
CVSS3
Base Score: 6.5
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
IMPACT SCORE
3.6
EXPLOITABILITY
2.8
CVE-2026-63260
SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead to denial of service via Excessive Allocation (CAPEC-130). An authenticated attacker with low-privilege access can trigger a denial of service condition in Kibana by sending a specially crafted, oversized request payload. Processing this user-supplied input requires resource-intensive memory allocation that can exhaust the available heap memory in the Kibana process, causing it to crash and become unavailable to all users.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 6.5)
CVSS3
Base Score: 6.5
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
IMPACT SCORE
3.6
EXPLOITABILITY
2.8
CVE-2026-63259
SUMMARY

Authorization Bypass Through User-Controlled Key (CWE-639) in Kibana can lead to information disclosure via user-supplied identifiers that reference scheduled query result data from Kibana Spaces the requester is not authorized to access.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 4.3)
CVSS3
Base Score: 4.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
IMPACT SCORE
1.4
EXPLOITABILITY
2.8
CVE-2026-63145
SUMMARY

Incorrect Authorization (CWE-863) in Kibana can lead to integrity compromise of Machine Learning audit and notification records via Accessing Functionality Not Properly Constrained by ACLs (CAPEC-1). A vulnerability exists in Kibana's Machine Learning functionality where a Machine Learning management endpoint performs an insufficient authorization check. The endpoint validates only a coarse privilege level but does not verify that the requesting user has access to the specific Machine Learning job or notification resources provided in the request. As a result, a low-privileged user with Machine Learning access in any Kibana space can manipulate Machine Learning audit and notification records for arbitrary jobs—including jobs in other spaces or belonging to other users—by leveraging Kibana's internally elevated credentials to write to restricted Machine Learning system indices that the user cannot access directly.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 4.3)
CVSS3
Base Score: 4.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N
IMPACT SCORE
1.4
EXPLOITABILITY
2.8
CVE-2026-63144
SUMMARY

Uncontrolled Recursion (CWE-674) in Elasticsearch can lead to denial of service via a specially crafted search request submitted by a low-privileged authenticated user. A user with read-level index access can submit a request that triggers unbounded recursive processing within the Elasticsearch query evaluation component, causing a fatal error that terminates the affected node. In single-node deployments, this results in complete service outage; in multi-node clusters, it causes repeated node restarts and sustained availability degradation.

PUBLISHED
Date2026-07-21
UPDATED
Date2026-07-21
RISK INFORMATION (Score: 6.5)
CVSS3
Base Score: 6.5
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H
IMPACT SCORE
3.6
EXPLOITABILITY
2.8